In contrast, in low-risk patients, only CD200+ cells could engraft primary and secondary recipients, which demonstrated self-renewal ability
In contrast, in low-risk patients, only CD200+ cells could engraft primary and secondary recipients, which demonstrated self-renewal ability. SULF1 antibody TTI-CD200 in vitro and in vivo. Treating mice with established disease significantly reduced disease burden and extended survival. These findings demonstrate that CD200 could be an attractive target for treating low-risk ALL, with minimal off-tumor […]
Recent Comments